Dr. Chalasani completed medical school in India before he moved to the USA to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), interim Chair of the Department of Medicine (2020-2021) and currently serves as the Vice President for Academic Affairs at Indiana University Health. He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years.
He has been continuously funded by the National Institutes of Health (NIH) since 1999, and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He was the lead author for the practice guideline on the diagnosis and management of nonalcoholic fatty liver disease by the AASLD published in 2012 and again in 2017 and also is the lead author for the diagnosis and management of drug induced liver injury by the American College of Gastroenterology. He is one of the most published and most cited investigators nationally in the USA, with more than 400 original scientific papers, Google Scholar H-Index 107 and 60,000 citations (as of June 2023).
He has mentored more than 100 trainees and junior faculty members with 19 of his former mentees in faculty positions at major academic centers and 12 are current or former recipients of federal funding. He is an elected member of the American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP). He and his colleagues from Indiana University are excited to collaborate with EtCurae and investigators throughout Mexico and Latin America.